The stock price of Immunic Inc (NASDAQ: IMUX) has surged by 2.54 when compared to previous closing price of 1.18, proactiveinvestors.com reported 2024-11-07 that Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple sclerosis (MS). During the third quarter ended September 30, 2024, the firm advanced both its phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and a twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) looking at orally available lead asset, nuclear receptor related 1 (Nurr1) activator, IMU-838.
Is It Worth Investing in Immunic Inc (NASDAQ: IMUX) Right Now?
The 36-month beta value for IMUX is also noteworthy at 1.90. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMUX is 87.44M, and at present, short sellers hold a 3.96% of that float. The average trading volume of IMUX on November 07, 2024 was 651.68K shares.
IMUX’s Market Performance
The stock of Immunic Inc (IMUX) has seen a 0.00% decrease in the past week, with a -19.33% drop in the past month, and a -9.02% fall in the past quarter. The volatility ratio for the week is 5.69%, and the volatility levels for the past 30 days are at 8.53% for IMUX. The simple moving average for the past 20 days is -11.34% for IMUX’s stock, with a -9.65% simple moving average for the past 200 days.
Analysts’ Opinion of IMUX
Many brokerage firms have already submitted their reports for IMUX stocks, with Leerink Partners repeating the rating for IMUX by listing it as a “Outperform.” The predicted price for IMUX in the upcoming period, according to Leerink Partners is $5 based on the research report published on September 09, 2024 of the current year 2024.
B. Riley Securities, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $6. The rating they have provided for IMUX stocks is “Buy” according to the report published on August 27th, 2024.
SVB Leerink gave a rating of “Mkt Perform” to IMUX, setting the target price at $5 in the report published on October 21st of the previous year.
IMUX Trading at -17.95% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.65% of loss for the given period.
Volatility was left at 8.53%, however, over the last 30 days, the volatility rate increased by 5.69%, as shares sank -12.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.79% lower at present.
During the last 5 trading sessions, IMUX rose by +1.63%, which changed the moving average for the period of 200-days by +6.93% in comparison to the 20-day moving average, which settled at $1.3657. In addition, Immunic Inc saw -19.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IMUX
The total capital return value is set at -1.47. Equity return is now at value -143.47, with -108.78 for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -75.75. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -46.57.
Currently, EBITDA for the company is -99.11 million with net debt to EBITDA at 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
In summary, Immunic Inc (IMUX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
